Home » FDA to Rely More on 510(k) Reviews Conducted by Third Parties
FDA to Rely More on 510(k) Reviews Conducted by Third Parties
The FDA released a comprehensive new plan that proposes to rely more on reviews conducted by third parties to streamline its review process and avoid re-reviews of 510(k) applications.
The plan is aimed at improving efficiency and consistency of the premarket notification process, with a goal to have 85 percent of third-party submissions not re-reviewed by the agency by 2021.
FDA Commissioner Scott Gottlieb said the third-party reviews “must be equivalent in rigor and completeness to the kinds of reviews that we’d conduct.”
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May